Vasculitis

Disease ID:1226
Name:Vasculitis
Associated with:0 target
3 immuno-relevant ligands
Synonyms
Angiitis
Description
Inflammation of the blood vessels.
Database Links
Disease Ontology: DOID:865

Targets

No target related data available for Vasculitis

Ligands

Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
avacopan
Immuno Disease Comments: Phase 3 clinical candidate for the chronic inflammatory disease, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis- see NCT02994927
Clinical Use: Avacopan (research code CCX168) is being evaluated in clinical trials for efficacy in ANCA-associated vasculitis (Phase 3 NCT02994927) and C3 glomerulopathy (Phase 2 NCT03301467). Phase 2 results in ANCA-associated vasculitis are reported in [1]. This study showed that avacopan can safely and effectively replace high dose glucocorticoid () therapy in patients with ANCA-associated vasculitis, hence progression to Phase 3 trial.. | View clinical data
methotrexate
Immuno Disease Comments: Approved drug for vasculitis.
Clinical Use: Anti-tumour agent used in the treatment of acute lymphocytic leukemia (ALL), meningeal leukemia, non-Hogkin's lymphoma, breast, lung and head and neck cancers. Also indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole, and in the treatment of autoimmune conditions including severe psoriasis and rheumatoid arthritis. The first oral methotraxate solution (Xatmep®) was FDA approved in April 2017 for the treatment of ALL and polyarticular juvenile idiopathic arthritis (pJIA) in pediatric patients. A 2017 a paper reported that a combination of methotrexate with leflunomide relieves the immune defects and ameliorates symptoms of rheumatoid arthritis [3]. | View clinical data
belimumab
Immuno Disease Comments: In clinical trial for this indication- see NCT01663623.
Clinical Use: Approved as an adjunctive treatment for systematic lupus erythematosus (SLE) [2]. The original formulation of belimumab was administered intravenously. In July 2017, a new self-injectable subcutaneous formulation of belimumab for the treatment of adult patients with active, autoantibody‑positive SLE was FDA approved, which allows patients to self-administer their medicine at home rather than going to medical facilities to receive their i.v. infusions.
Additional indications being evaluated with belimumab include vasculitis (Phase 3), and myaesthenia gravis and transplant rejection (both Phase 2). | View clinical data

References

Show »

1. Jayne DRW, Bruchfeld AN, Harper L, Schaier M, Venning MC, Hamilton P, Burst V, Grundmann F, Jadoul M, Szombati I et al.. (2017) Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. J. Am. Soc. Nephrol., 28 (9): 2756-2767. [PMID:28400446]

2. Lutalo PM, D'Cruz DP. (2014) Update on belimumab for the management of systemic lupus erythematosus. Expert Opin Biol Ther, 14 (11): 1701-8. [PMID:25303323]

3. Zhong W, Zhao L, Liu T, Jiang Z. (2017) IL-22-producing CD4+T cells in the treatment response of rheumatoid arthritis to combination therapy with methotrexate and leflunomide. Sci Rep, 7: 41143. [PMID:28117352]